What is the current Price Target for the Bridgebiocology Therapeut stock?

The average Bridgebiocology Therapeut target price is $22.44. This is 476.86% higher than the current stock price. The highest price target is 682.78%, the lowest is 289.46%. 12 Analysts have issued a price target Bridgebiocology Therapeut 2027 .

How high will the Bridgebiocology Therapeut stock rise?

No reliable answer can be given as to how high the Bridgebiocology Therapeut stock will rise. The performance of stocks, including the Bridgebiocology Therapeut stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Bridgebiocology Therapeut stock today?

The performance of Bridgebiocology Therapeut stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Bridgebiocology Therapeut stock fall?

The decline in Bridgebiocology Therapeut stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Bridgebiocology Therapeut Forecast, price target & analysts

$3.89

1.27%

Nasdaq, Oct 02, 04:00 pm EDT. Closed.

ISIN

US1079241022

Symbol

BBOT

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Bridgebiocology Therapeut Target price 2026 - Analyst rating & recommendation

Bridgebiocology Therapeut Classifications & Recommendation

Buy

94%

Hold

Bridgebiocology Therapeut Price Target

Target Price	$22.44
Price	$3.89
Potential	476.86% register free of charge
Number of Estimates	12

	12 Analysts have issued a price target Bridgebiocology Therapeut 2027 . The average Bridgebiocology Therapeut target price is $22.44. This is 476.86% register free of charge higher than the current stock price. The highest price target is $30.45 682.78% register free of charge , the lowest is $15.15 289.46% register free of charge .
	A rating was issued by 17 analysts: 16 Analysts recommend Bridgebiocology Therapeut to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Bridgebiocology Therapeut stock has an average upside potential 2027 of 476.86% register free of charge . Most analysts recommend the Bridgebiocology Therapeut stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-4.30	-2.62
	357.45%	39.07%
P/E		negative

13 Analysts have issued a Bridgebiocology Therapeut forecast for earnings per share. The average Bridgebiocology Therapeut EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-4.30	357.45%
2026	$-2.62 39.07% unlock
2027	$-2.52 3.82% unlock
2028	$-2.49 1.19% unlock
2029	$-2.09 16.06% unlock
2030	$-1.38 33.97% unlock
2031	$-1.81 31.16% unlock
2032	$-0.75 58.56% unlock
2033	$0.78 204.00% unlock

Current	-1.71	102.93%
2026	-1.48 13.64% unlock
2027	-1.54 4.05% unlock
2028	-1.56 1.30% unlock
2029	-1.86 19.23% unlock
2030	-2.82 51.61% unlock
2031	-2.15 23.76% unlock
2032	-5.19 141.40% unlock
2033	5.02 196.72% unlock

Bridgebiocology Therapeut...

Current Bridgebiocology Therapeut Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
JP Morgan	Locked ➜ Locked	Locked	Sep 11 2026
Leerink Partners	Locked ➜ Locked	Locked	Sep 10 2026
Canaccord Genuity	Locked ➜ Locked	Locked	Sep 09 2026
Raymond James	Locked ➜ Locked	Locked	Sep 09 2026
Stifel	Locked ➜ Locked	Locked	Sep 09 2026
Wedbush	Locked ➜ Locked	Locked	Sep 09 2026
JP Morgan	Locked ➜ Locked	Locked	Aug 14 2026

Analyst Rating	Date
Locked JP Morgan: Locked ➜ Locked	Sep 11 2026
Locked Leerink Partners: Locked ➜ Locked	Sep 10 2026
Locked Canaccord Genuity: Locked ➜ Locked	Sep 09 2026
Locked Raymond James: Locked ➜ Locked	Sep 09 2026
Locked Stifel: Locked ➜ Locked	Sep 09 2026
Locked Wedbush: Locked ➜ Locked	Sep 09 2026
Locked JP Morgan: Locked ➜ Locked	Aug 14 2026

Discover more stocks with a high price target

NIO ADR 86.90%

Alibaba Group Holding Ltd 81.89%

Rheinmetall 70.55%

Tencent Holdings Ltd. 61.28%

Adyen 56.67%

Uber Technologies 51.26%

BYD 50.30%

Siemens Energy 43.79%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now